From: A machine learning model for classifying G-protein-coupled receptors as agonists or antagonists
Drug name | Target | FDA-approved action | T-model-predicted action | A-model-predicted action | References |
---|---|---|---|---|---|
Beclometasone dipropionate | Glucocorticoid receptor | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Adenosine | Adenosine receptor A1 | GPCR-agonist | GPCR-nontarget | GPCR-agonist | [16] |
Regadenoson | Adenosine receptor A2a | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Nicardipine | Alpha-1A adrenergic receptor | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Oxymetazoline | Alpha-2B adrenergic receptor | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Prazosin | Alpha-1A adrenergic receptor | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Apraclonidine | Alpha-2A adrenergic receptor | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Dexmedetomidine | Alpha-2A adrenergic receptor | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Acebutolol | Beta-1 adrenergic receptor | GPCR-agonist | GPCR-nontarget | GPCR-antagonist | [16] |
Mirabegron | Beta-3 adrenergic receptor | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Candesartan | Type-1 angiotensin II receptor | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Pentagastrin | Gastrin/cholecystokinin type B receptor | GPCR-agonist | GPCR-nontarget | GPCR-agonist | [16] |
Maraviroc | C–C chemokine receptor type 5 | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Biperiden | Muscarinic acetylcholine receptor M1 | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Propantheline | Muscarinic acetylcholine receptor M1 | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Umeclidinium | Muscarinic acetylcholine receptor M1 | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Nabilone | Cannabinoid receptor 2 | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Zafirlukast | Cysteinyl leukotriene receptor 1 | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Dopamine | Dopamine D2 receptor | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Ambrisentan | Endothelin-1 receptor | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Bosentan | Endothelin-1 receptor | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Vorapaxar | Proteinase-activated receptor 1 | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Baclofen | Gamma-aminobutyric acid type B receptor subunit 2 | GPCR-agonist | GPCR-nontarget | GPCR-agonist | [16] |
Estradiol | Estrogen receptor alpha | GPCR-agonist | GPCR-nontarget | GPCR-agonist | [16] |
Levodopa | Dopamine D1 receptor | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Dronabinol | Cannabinoid receptor 1 | GPCR-agonist | GPCR-nontarget | GPCR-agonist | [16] |
Bumetanide | Solute carrier family 12 member 1 | GPCR-antagonist | GPCR-target | GPCR-agonist | [16] |
Nicotinic acid | Hydroxycarboxylic acid receptor 3 | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Suvorexant | Orexin receptor type 1 | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Cetirizine | Histamine H1 receptor | GPCR-antagonist | GPCR-target | GPCR-agonist | [16] |
Betazole | Histamine H2 receptor | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Clozapine | Dopamine D2 receptor | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Frovatriptan | 5-hydroxytryptamine receptor 1D | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Eletriptan | 5-hydroxytryptamine receptor 1D | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Ergotamine | 5-hydroxytryptamine receptor 1D | GPCR-agonist | GPCR-target | GPCR-antagonist | [16] |
Amoxapine | Sodium-dependent serotonin transporter | GPCR-antagonist | GPCR-nontarget | GPCR-antagonist | [16] |
Lurasidone | Dopamine D2 receptor | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Chloroquine | Glutathione S-transferase A2 | GPCR-antagonist | GPCR-target | GPCR-agonist | [16] |
Tasimelteon | Melatonin receptor type 1A | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Niclosamide | DNA | GPCR-antagonist | GPCR-nontarget | GPCR-antagonist | [16] |
Levocabastine | Histamine H1 receptor | GPCR-antagonist | GPCR-target | GPCR-agonist | [16] |
Naltrexone | Delta-type opioid receptor | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Anileridine | Mu-type opioid receptor | GPCR-agonist | GPCR-target | GPCR-antagonist | [16] |
Alfentanil | Mu-type opioid receptor | GPCR-agonist | GPCR-target | GPCR-antagonist | [16] |
Cangrelor | P2Y purinoceptor 12 | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Treprostinil | Prostacyclin receptor | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Indomethacin | Prostaglandin G/H synthase 2 | GPCR-antagonist | GPCR-target | GPCR-agonist | [16] |
Prostaglandin E1 | Prostaglandin E2 receptor EP2 subtype | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Prostaglandin E2 | Prostaglandin E2 receptor EP2 subtype | GPCR-agonist | GPCR-nontarget | GPCR-agonist | [16] |
Misoprostol | Prostaglandin E2 receptor EP3 subtype | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Latanoprost | Prostaglandin F2-alpha receptor | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Epoprostenol | P2Y purinoceptor 12 | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Sonidegib | Smoothened homolog | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Aprepitant | Neurokinin 1 receptor | GPCR-antagonist | GPCR-target | GPCR-antagonist | [16] |
Iloprost | Prostacyclin receptor | GPCR-agonist | GPCR-target | GPCR-agonist | [16] |
Droxidopa | Alpha-1A adrenergic receptor | GPCR-agonist | GPCR-target | GPCR-agonist | [5] |
Naloxegol | Mu-type opioid receptor | GPCR-antagonist | GPCR-nontarget | GPCR-agonist | [5] |
Netupitant | Neurokinin 1 receptor | GPCR-antagonist | GPCR-target | GPCR-antagonist | [5] |
Olodaterol | Beta-2 adrenergic receptor | GPCR-agonist | GPCR-target | GPCR-agonist | [5] |
Rolapitant | Neurokinin 1 receptor | GPCR-antagonist | GPCR-target | GPCR-antagonist | [5] |
Selexipag | Prostacyclin receptor | GPCR-agonist | GPCR-target | GPCR-agonist | [5] |
Pimavanserin | 5-hydroxytryptamine receptor 2A | GPCR-agonist | GPCR-target | GPCR-agonist | [5] |
Naldemedine | Mu-type opioid receptor | GPCR-antagonist | GPCR-nontarget | GPCR-antagonist | [5] |